abstract |
The present invention relates to a IL-1 antagonist alone or in combination with other therapeutic agents and relative pharmaceutical compositions for use for the treatment and/or prevention of toxicity induced by a T cell therapy, wherein the T cell expresses at least one recombinant receptor. |